Recent CING News
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25 • Newsfile • 04/06/2026 08:34:00 PM
- Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights • GlobeNewswire Inc. • 03/18/2026 12:00:00 PM
- Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 02/17/2026 01:00:00 PM
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 • Newsfile • 11/18/2025 09:27:00 PM
- Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2025 01:00:00 PM
- Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 • GlobeNewswire Inc. • 11/10/2025 01:00:00 PM
- Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting • GlobeNewswire Inc. • 10/23/2025 08:45:00 PM
- FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date • GlobeNewswire Inc. • 10/14/2025 12:00:00 PM
- Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment • GlobeNewswire Inc. • 09/17/2025 12:45:00 PM
- Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights • GlobeNewswire Inc. • 08/19/2025 12:45:00 PM
- Cingulate Provides Management Team Update • GlobeNewswire Inc. • 08/15/2025 01:00:00 PM
- Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 • GlobeNewswire Inc. • 08/06/2025 12:45:00 PM
- Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301 • GlobeNewswire Inc. • 07/29/2025 12:00:00 PM
- Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application • GlobeNewswire Inc. • 07/09/2025 12:00:00 PM
- Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD • GlobeNewswire Inc. • 05/20/2025 12:00:00 PM
- FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 • GlobeNewswire Inc. • 05/14/2025 12:00:00 PM
- Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets • GlobeNewswire Inc. • 05/08/2025 08:30:00 PM
- Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD • GlobeNewswire Inc. • 04/29/2025 12:00:00 PM
- Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone) • GlobeNewswire Inc. • 04/09/2025 12:00:00 PM
